<DOC>
	<DOCNO>NCT02358538</DOCNO>
	<brief_summary>To evaluate efficacy open-label ganaxolone adjunctive therapy uncontrolled seizure female child PCDH19 mutation rare genetic epilepsy open-label proof-of-concept study .</brief_summary>
	<brief_title>A Multicenter , Open-Label Proof-of-Concept Trial Ganaxolone Children With PCDH19 Female Pediatric Epilepsy Other Rare Genetic Epilepsies</brief_title>
	<detailed_description>The purpose proof-of-concept study evaluate ganaxolone adjunctive therapy uncontrolled seizure female child PCDH19 mutation rare genetic epilepsy . After establish baseline seizure frequency , qualify subject enter study treat open-label ganaxolone six month .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Pregnanolone</mesh_term>
	<criteria>Key 1 . Have parent legal guardian available willing give write informed consent . 2 . Male female outpatient 2 18 year age year age time consent . 3 . Have follow epilepsy syndrome : PCDH19 ; CDKL5 ; Dravet Syndrome ; Lennox Gastaut Syndrome ( LGS ) ; Continuous Spikes Waves Sleep ( CSWS ) 4 . Have uncontrolled cluster seizure and/or nonclustered seizure . 5 . Subjects stable regimen antiepileptic medication , generally good health . 6 . Parent guardian able willing maintain accurate complete daily write seizure calendar . 7 . Able willing take study medication food , two three time daily . Key Exclusion Criteria 1 . Have previous exposure ganaxolone . 2 . Known sensitivity allergy component study drug , progesterone , relate steroid compound . 3 . Exposure investigational drug device &lt; 90 day prior screen , plan participate another drug device trial time study . 4 . Concurrent use vigabatrin , tiagabine , ezogabine permit . 5 . Have medical condition , investigator 's judgment , consider clinically significant could potentially affect subject safety study outcome , include limited : clinically significant cardiac , renal , pulmonary , gastrointestinal , hematologic hepatic condition ; condition affect absorption , distribution , metabolism excretion drug . 6 . Have active suicidal plan/intent , active suicidal thought past 6 month suicide attempt past 3 year . 7 . Have Alanine transferase ( ALT ; SGPT ) Aspartate transferase ( AST ; SGOT ) level &gt; 3 time upper limit normal ( ULN ) , total bilirubin &gt; 1.5 time ULN screen baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>PCDH19</keyword>
	<keyword>ganaxolone</keyword>
	<keyword>neurosteroid</keyword>
	<keyword>CDKL5</keyword>
	<keyword>LGS</keyword>
	<keyword>CSWS</keyword>
</DOC>